Exocrine pancreatic carcinoma

This early-phase study tests a combination of two targeted drugs (vismodegib and erlotinib) with or without a standard chemotherapy drug (gemcitabine) in people with advanced pancreatic cancer or other solid tumors that cannot be removed by surgery. The main goal is to find the s…

This phase 1 trial tests an experimental cell therapy called IX001 TCR-T in adults with advanced pancreatic or colorectal cancer that has not responded to at least two standard treatments. The therapy uses a patient's own immune cells, engineered to recognize cancer cells with KR…

Researchers at Duke University are testing whether combining the Whipple procedure with surgical removal or ablation of liver tumors can help people with stage IV pancreatic cancer that has spread only to the liver. The study enrolls 18 adults who are healthy enough for major sur…

This phase II trial is testing whether combining two targeted drugs, palbociclib and binimetinib, can help people with cancers that have RAS mutations. The study includes patients with pancreatic cancer, ovarian cancer, and other solid tumors. Researchers want to see if the drug …

This early-stage trial is testing an investigational drug called GKL-006, given alongside standard chemotherapy, in people with advanced pancreatic cancer that cannot be removed by surgery. The study aims to see if the combination is safe and tolerable, and whether it shows any p…

This early-phase study tests a combination of two drugs, niraparib and dostarlimab, in 18 adults with BRCA-mutated breast, pancreas, or ovary cancer that has spread or cannot be surgically removed. Niraparib blocks a DNA repair protein in cancer cells, while dostarlimab helps the…

This phase 2 trial is testing the drug talazoparib in people with advanced solid tumors that have specific mutations in DNA repair genes. Talazoparib works by blocking a protein called PARP, which cancer cells use to fix their damaged DNA, leading to cancer cell death. The study …

This early-phase trial is testing whether an experimental oral drug called BXCL701 can change how the immune system responds to pancreatic cancer. The study will enroll people with untreated, locally advanced or metastatic pancreatic cancer who can undergo tumor biopsies before a…

This phase 2 trial is testing the safety and effectiveness of glipizide, a standard diabetes drug, for lowering blood sugar in people with pancreatic cancer. The study includes 29 participants with active pancreatic cancer and high blood sugar. Researchers will measure blood suga…

This early-phase trial tests a new drug called M6620 (berzosertib) combined with the chemotherapy irinotecan in people with advanced solid tumors that have spread or can't be removed. The goal is to find the safest dose and see if the combination can slow tumor growth. About 66 p…

This trial tests an experimental antibody, PBP1510, designed to block a protein called PAUF that may help pancreatic cancer grow. The study includes two parts: first, finding a safe dose of PBP1510 alone or with the chemotherapy gemcitabine; second, testing the best dose in a lar…

This study tests a drug called tisotumab vedotin, alone or with other cancer medicines, in people with advanced colorectal, lung, pancreatic, or head and neck cancers that have stopped responding to standard treatments. About 350 participants receive different dosing schedules to…

This trial compares changing the dressing on a PICC line (a type of central catheter) every week versus every two weeks in people with colon or pancreas cancer receiving chemotherapy. The goal is to see if less frequent changes are just as safe, with no increase in skin injuries,…

This early-phase trial is testing whether combining the targeted drug olaparib, the immunotherapy durvalumab, and radiation therapy is safe for people with locally advanced pancreatic cancer that cannot be surgically removed. The study enrolls 18 participants who have already rec…

This phase 2 trial tests whether adding galeterone to standard chemotherapy (gemcitabine) can shrink tumors or slow disease in people with advanced pancreatic cancer that has not responded to prior treatments. The study enrolls about 15 adults with metastatic disease who have alr…

This early-phase trial tests an experimental drug called IPH5301, which targets a protein called CD73 on cancer cells. The study involves 27 people with advanced solid tumors, including breast, lung, and pancreatic cancers. In the first part, IPH5301 is given alone to find a safe…

This study tests a combination of two drugs, cediranib and olaparib, in people with advanced solid tumors that have spread or cannot be removed by surgery. The cancers include certain types of breast, lung, and pancreatic cancer. The goal is to see if the combination can shrink t…

This early-stage trial tests whether adding the drug bosentan to standard chemotherapy (gemcitabine and nab-paclitaxel) is safe and tolerable for people with pancreatic cancer that cannot be removed by surgery. The study involves 21 adults and aims to find the best dose of bosent…

This study tests whether combining three immunotherapy drugs (domvanalimab, zimberelimab, and APX005M) can safely control metastatic pancreatic cancer. The trial enrolls 46 people whose cancer has spread and standard treatments have stopped working. Researchers will monitor side …

This early-phase trial is testing a combination of two drugs—guadecitabine and durvalumab—in 55 people with advanced liver, pancreatic, bile duct, or gallbladder cancers that have spread. Guadecitabine aims to stop cancer cell growth, while durvalumab helps the immune system atta…

This study tests if washing the abdomen with distilled water or saline right after removing a pancreatic tumor can help patients live longer. About 845 adults having surgery for pancreatic or related cancers are randomly assigned to one of three groups: washing with saltwater, wa…

This early-stage trial is testing a combination of pelareorep (a reovirus) and atezolizumab (an immunotherapy) along with standard chemotherapies in people with advanced anal or pancreatic cancers. The study aims to find safe doses, look for biomarkers that predict response, and …

This early-phase study tests a new treatment called EGFR-BATs for people with advanced pancreatic cancer that has not responded to standard chemotherapy. The treatment uses the patient's own immune cells, which are trained in a lab to better attack cancer cells. The main goal is …

This study tests whether adding a drug called defactinib to targeted radiation therapy can help control advanced pancreatic cancer better than radiation alone. About 42 people with inoperable pancreatic cancer will take part. The goal is to see if the combination slows cancer gro…

This early-phase trial tests a new drug called sEphB4-HSA combined with standard chemotherapy in people with advanced or metastatic solid tumors, including head and neck, pancreatic, lung, and gallbladder cancers. The goal is to find the best dose and see if the combination is sa…

This study tests a drug called ceralasertib, alone or with olaparib or durvalumab, in people with advanced solid tumors like kidney, bladder, pancreatic, and endometrial cancers. The goal is to see if these combinations can shrink tumors by blocking enzymes that help cancer grow.…

This study tests whether adding a special ultrasound device called Suizenji to standard chemotherapy helps people with advanced pancreatic cancer that didn't respond to initial treatment. About 90 adults whose cancer cannot be removed by surgery will receive either chemo alone or…

This study tests whether taking pancreatic enzymes (Pertzye) with meals can help people with metastatic pancreatic cancer maintain their body weight during chemotherapy. The trial includes 17 participants who are starting a standard chemo regimen called FOLFIRINOX. Researchers wi…

This early-phase study tests a combination of two targeted drugs, palbociclib and gedatolisib, in people with advanced lung, pancreatic, head & neck, or other solid tumors that have stopped responding to standard treatments. The main goal is to find the safest dose and look for e…

This early-phase trial is testing whether adding the diabetes drug metformin and a specific dietary supplement (including curcumin, vitamins, and other natural compounds) to standard chemotherapy (gemcitabine and abraxane) is safe and feasible for people with pancreatic cancer th…

This phase 1 trial tests a vaccine (p53MVA) that trains the immune system to attack cancer cells with a p53 mutation, given together with the immunotherapy drug pembrolizumab (Keytruda). The study includes 11 people with advanced solid tumors like lung, head and neck, liver, kidn…

This early-phase study tests a new drug called OMO-103, which blocks a cancer-driving protein called MYC, combined with standard chemotherapy in 26 people with metastatic pancreatic cancer who have not had prior treatment for advanced disease. The main goals are to check safety a…

This phase II/III trial compares a three-drug chemotherapy combination (nab-paclitaxel, gemcitabine, plus cisplatin) against the standard two-drug combo (nab-paclitaxel plus gemcitabine) in people with metastatic pancreatic cancer that has BRCA1, BRCA2, or PALB2 gene mutations. T…

This study looks at whether giving chemotherapy first can shrink pancreatic tumors that have grown into nearby arteries, making them safe to remove with surgery. Researchers want to see if this approach can completely remove the cancer without leaving any behind. Only 2 people ar…

This trial tests a new approach for people with advanced cancers that have a specific genetic change called KRAS G12V. Patients receive their own immune cells that have been genetically modified to recognize and attack the cancer. They also get chemotherapy and an immunotherapy d…

This study was designed to test a new drug called GFH375 in people with advanced pancreatic cancer that has a specific genetic change (KRAS G12D). The goal was to see if the drug could shrink tumors or slow the disease. However, the study was withdrawn before any participants wer…

This early-stage trial is testing whether a combination of three widely used drugs—metformin (for diabetes), digoxin (for heart conditions), and simvastatin (for cholesterol)—can be safely given to people with advanced pancreatic cancer or other solid tumors that have stopped res…

This early-phase trial tests whether adding a targeted drug called ivosidenib to standard chemotherapy can help shrink pancreatic tumors before surgery. About 16 people with resectable pancreatic cancer that has a specific gene mutation (IDH1) will receive the drug combination fo…

This early-phase trial explores whether two experimental PET/CT tracers, 68Ga-FAPI-46 and 68Ga-PSMA-11, can accurately highlight various non-prostate cancers, including breast, lung, and pancreatic tumors. Participants scheduled for surgery will receive the tracers before their s…

This pilot study is testing whether routine MRI scans can find early signs of pancreatic cancer in people who carry BRCA, ATM, or PALB2 gene mutations, which raise their risk. About 250 participants will undergo MRI, MRCP, endoscopic ultrasound, and provide blood, tissue, and sal…

This early-phase trial tests a radioactive imaging agent called Technetium-99m HYNIC-FAPI in 15 people with metastatic lung, pancreas, breast, or colorectal cancer. The goal is to see how well it highlights tumors on SPECT/CT scans. Researchers will measure where the agent goes i…

This study is testing a new imaging agent called 18F-FSPG to see if it can better detect liver cancer (hepatocellular carcinoma) and other liver tumors compared to standard PET scans. About 110 adults with liver cancer or benign liver tumors will receive the tracer before their s…

This study tests a new radioactive tracer called 18F-alphavbeta6-binding-peptide to see if it can safely and clearly show cancers in the breast, colon, lung, or pancreas. About 27 adults with these cancers will get the tracer and have a PET scan. The goal is to find out if this m…

This study tests whether using telemedicine and remote monitoring can help people with advanced digestive cancers manage chemotherapy side effects at home, reducing the need for emergency room visits and hospital stays. About 750 patients and their caregivers will receive enhance…

This study looks at whether acupuncture can help manage pain after open abdominal surgery for colorectal or pancreatic cancer. About 70 patients will either receive acupuncture or standard care. The goal is to see if acupuncture reduces pain and the need for opioid painkillers, h…

This study aimed to see if a food supplement called ARACOMPLEX® could help maintain quality of life in patients with advanced pancreatic cancer receiving chemotherapy. The supplement contains maca extract, vitamins, and minerals. However, the trial was withdrawn before enrolling …

This study tests a web-based education tool called HOPE-Genomics that teaches cancer patients about their genetic test results. About 465 adults with breast, colorectal, lung, ovarian, pancreatic, or prostate cancer are taking part. The goal is to see if the tool helps patients r…

This phase II trial, called MATCH, is testing whether treating cancer based on the genetic makeup of a patient's tumor works better than standard treatments. Over 6,400 adults with advanced solid tumors, lymphomas, or multiple myeloma that have not responded to prior therapy are …

This study looks at whether a blood test that measures tumor DNA (ctDNA) can predict how well chemotherapy is working in people with advanced pancreatic cancer. Researchers will compare the blood test results with CT scans taken before and two months after starting treatment. The…

This pilot study at Mayo Clinic tests whether personalized education and genetic counseling can increase genetic testing in people with a first-degree relative who had pancreatic cancer. About 50 participants will receive tailored information and counseling. The goal is to see if…

This study reviews medical records from 300 cancer patients to see if the makeup of a tumor's surroundings (the tumor microenvironment) is linked to how well antibody-based therapies work. Researchers will analyze tissue samples and blood markers from patients with seven types of…

This study looks at whether a biomarker called GATA6 can help predict how well patients with resectable pancreatic cancer respond to chemotherapy before and after surgery. About 84 participants will provide tumor samples to measure GATA6 levels, then receive a standard chemo regi…